HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

In addition to Berenberg Bank, Moderna also received a Hold from HSBC’s Yifeng Liu in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Moderna (NASDAQ: ...

Live Updates Stocks on the Move Today 9:49 am Here are some notable stocks on the move today: Super Micro Computer: The ...

Stocks rebounded after last week’s slide as Treasuries stabilized after 10-year yields approached 4.5%, with traders keeping ...

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface … Yet, these strange ...

Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...

US stocks finished mixed on Monday ahead of a busy week for corporate earnings, though the Nasdaq managed to push higher, led by gains from Tesla.

Asian equities are poised to track Wall Street stocks higher as Treasuries halted a selloff that drove 10-year yields near ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...